Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual ...

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., and Ube Corp. have received FDA approval for their Omlonti 0.002 percent eye drops, which are designed to reduce elevated intraocular ...

Fluctuations in blood pressure over an extended period, along with their interaction with mean blood pressure or intraocular pressure, are associated with a more rapid visual field progression in ...

High intraocular pressure (IOP) is a significant risk factor for glaucoma. Current IOP tests are mostly conducted in hospitals, while portable home tonometers that provide convenient IOP monitoring ...

SpyGlass Pharma has reported early human data on its drug-eluting intraocular lens. The first-in-human clinical trial linked the bimatoprost delivery devices to a 45% reduction in intraocular pressure ...

Researchers have developed contact lenses with embedded sensors that measure the pressure inside the eye and send the information to an ophthalmologist for evaluation. It’s hoped that the lens will ...

Optometrists, ophthalmologists and their patients will benefit from new, high-tech tools to detect glaucoma at its earliest stages thanks to a startup that will commercialize smart contact lenses ...

Shuchi Patel, MD: Good afternoon, Dr. Ruth Williams. Thank you so much for taking the time to have a discussion with us regarding a topic that is of emerging interest. Today we're going to talk about ...

Although primary open-angle glaucoma (POAG) is the leading cause of blindness in people over the age of 55, there remains no cure for the disease and its biological mechanisms are not well understood.